2-propoxymethyl pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-propoxymethyl pyridine
• 英文别名: 2-(Propoxymethyl)pyridine
• 化学式: C₉H₁₃NO
• 分子量: 151.208
• InChiKey: RMXZBAFYMUWXRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-吡啶甲醇 在 Crabtree catalyst 氢气 、 sodium hydride 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 47.0h， 生成 2-propoxymethyl pyridine
  参考文献：
  名称：

  Auxiliary accelerated reactions: Towards the use of catalytic chiral auxiliaries

  摘要：

  In competition experiments, the acceleration of reactivity of alkenes tethered to pyridyl groups compared with the corresponding alkenes tethered to phenyl groups in the presence of transition metals was demonstrated for two reaction types: Diels-Alder cycloaddition of enoate esters and catalytic hydrogenation of allylic and homoallylic ethers. The rate accelerations observed are of crucial importance in the development of a new concept for asymmetric catalysis: chiral auxiliaries which can function in a catalytic manner. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4020(97)00829-6

文献信息

• [EN] SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS<br/>[FR] PETITES MOLÉCULES INDUCTRICES DE GDNF COMME NOUVELLE THÉRAPEUTIQUE POSSIBLE DES TROUBLES NEUROPSYCHIATRIQUES
  申请人：UNIV COLUMBIA

  公开号：WO2013028999A1

  公开（公告）日：2013-02-28

  The invention provides a compound having the structure (I), wherein A is a substituted or unsubstituted ring; Z is present or absent and when present is (II), wherein n is 0, 1, 2, 3, or 4; Y is -(CR11R12)-, -NH(CR11R12)- or -O(CR11R12)- wherein R11 and R12 are each hydrogen or combine to form a carbonyl; and wherein R1 to R10 are herein as described.

  本发明提供了一种具有结构（I）的化合物，其中A是取代的或未取代的环；Z是否存在，如果存在则为（II），其中n为0，1，2，3或4；Y是-(CR11R12)-，-NH(CR11R12)-或-O(CR11R12)-，其中R11和R12分别是氢或结合形成一个羰基；以及其中R1至R10如本文所述。
• Fused Heterocyclic Compounds as Ion Channel Modulators
  申请人：Kobayashi Tetsuya

  公开号：US20120010192A1

  公开（公告）日：2012-01-12

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类是钠通道抑制剂的化合物，以及它们在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。在特定实施例中，该类化合物的结构由式I给出：其中R1、R2、R3、R4和R5如本文所述，以及制备和使用该类化合物的方法，以及含有这些化合物的药物组合物。
• Auxiliary accelerated reactions: catalytic hydrogenation
  作者：Andrew D. Westwell、Jonathan M. J. Williams

  DOI：10.1039/p19960000001

  日期：——

  In competition experiments, alkenes tethered to pyridyl groups were found to undergo iridium catalysed hydrogenation more quickly than alkenes tethered to phenyl groups. This is in marked contrast to the results for hydrogenation of some of the individual substrates where alkenes tethered to pyridyl groups were reduced much more slowly than their phenyl counterparts.

  在竞争实验中，连接至吡啶基的烯烃被发现比连接至苯基的烯烃更快地经历铱催化氢化。这与一些单一底物的氢化结果形成了鲜明对比，其中连接至吡啶基的烯烃的还原速度远低于其苯基对应物。
• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Corkey Britton

  公开号：US20110021521A1

  公开（公告）日：2011-01-27

  The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein W 1 , W 2 , W 3 , R 1 , Q, X 1 , X 2 and X 3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本发明涉及一类钠通道抑制剂化合物，以及它们在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。具体实施例中，该化合物的结构由下式给出：其中W1、W2、W3、R1、Q、X1、X2和X3如本文所述，以及制备和使用该化合物的方法，以及含有该化合物的药物组合物。
• FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE
  申请人：Milne Jill C.

  公开号：US20130059801A1

  公开（公告）日：2013-03-07

  The invention relates to fatty acid amides; compositions comprising an effective amount of a fatty acid amide; and methods for treating or preventing cancer, a metabolic disease or a neurodegenerative disease comprising the administration of an effective amount of a fatty acid amide.

  本发明涉及脂肪酸酰胺；包含有效量的脂肪酸酰胺的组合物；以及治疗或预防癌症、代谢性疾病或神经退行性疾病的方法，其中包括给予有效量的脂肪酸酰胺。